Atomo Diagnostics Limited (ASX:AT1) Completes $3.1M Capital Raise and Board Restructure
Atomo Diagnostics Limited (ASX:AT1) completes a $3.1 million capital raise and announces a board restructure to enhance operational efficiency and drive growth.
Atomo Diagnostics Limited (ASX:AT1) completes a $3.1 million capital raise and announces a board restructure to enhance operational efficiency and drive growth.
Proteomics International (ASX:PIQ) launches PromarkerD test in Australia and secures $4.5m funding to support its precision diagnostics growth.
Lumos Diagnostics (ASX:LDX) expands Medicare reimbursement for FebriDx to over 55% of US coverage, enhancing market access.
Telix Pharmaceuticals Limited (ASX:TLX) reports a 62% increase in Q1 2025 revenue, reaching $186M.
Clarity Pharmaceuticals (ASX:CU6) secures a copper-64 supply agreement with Nusano to support clinical trials and commercialization.
Anatara Lifesciences (ASX:ANR) reports Phase II GaRP-IBS trial results, highlighting safety and significant improvements in anxiety scores.
Imricor Medical Systems (ASX:IMR) secures CE Mark approval for its Advantage-MR system under the new EU Medical Device Regulation, anticipating EU launch in June.
PainChek Ltd (ASX:PCK) secures a $1.41m R&D tax refund, advances FDA review for its Adult App, and launches the Infant App on Apple App Store.
4DMedical Limited (ASX:4DX) lodges a supplementary prospectus amending the terms of its New and Piggyback Options offers.
Pro Medicus Limited (ASX:PME) enters a multi-year AI research collaboration with UCSF to advance healthcare imaging solutions.